IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s Disease December 1, 2022December 1, 2022 by Alejandro IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC AD1 For The Treatment Of Agitation In Dementia From Alzheimer’s Disease (1)
